Arkolith/Insider Trading/JNCE/Form 4

Tang Kevin C

Director, 10% OwnerJounce Therapeutics, Inc. (JNCE) · full profile →Form 4 · filed May 5, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 3, 2023Tender(U)5.3M$1.85$9.8M0
May 3, 2023Other(J)10K$9737.70$97.4M10K

Transaction Codes

U
See SEC Form 4 code table
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-027688) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML